165 related articles for article (PubMed ID: 34917417)
1. The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein.
Mehrabani N; Vaezi Kakhki MR; Javid H; Ebrahimi S; Hashemy SI
Neurol Res Int; 2021; 2021():9966000. PubMed ID: 34917417
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system.
Ghahremani F; Sabbaghzadeh R; Ebrahimi S; Javid H; Ghahremani J; Hashemy SI
Iran J Basic Med Sci; 2021 Apr; 24(4):499-505. PubMed ID: 34094032
[TBL] [Abstract][Full Text] [Related]
3. The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
Zarei Shandiz S; Assaran Darban R; Javid H; Ghahremanloo A; Hashemy SI
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; ():. PubMed ID: 38334824
[TBL] [Abstract][Full Text] [Related]
4. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
5. The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.
Korfi F; Javid H; Assaran Darban R; Hashemy SI
Biochem Res Int; 2021; 2021():6620708. PubMed ID: 33976938
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
Rezaei S; Assaran Darban R; Javid H; Hashemy SI
Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
[TBL] [Abstract][Full Text] [Related]
7. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
8. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
[TBL] [Abstract][Full Text] [Related]
10. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
11. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
[TBL] [Abstract][Full Text] [Related]
12. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
[TBL] [Abstract][Full Text] [Related]
13. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
Golestaneh M; Firoozrai M; Javid H; Hashemy SI
Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316
[TBL] [Abstract][Full Text] [Related]
14. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
15. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).
Chernova I; Lai JP; Li H; Schwartz L; Tuluc F; Korchak HM; Douglas SD; Kilpatrick LE
J Leukoc Biol; 2009 Jan; 85(1):154-64. PubMed ID: 18835883
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a New CaMKII-Targeted Synthetic Lethal Therapy against Glioblastoma Stem-like Cells.
Han JM; Kim YJ; Jung HJ
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267623
[TBL] [Abstract][Full Text] [Related]
18. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
[TBL] [Abstract][Full Text] [Related]
19. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
[TBL] [Abstract][Full Text] [Related]
20. Substance P enhances the local activation of NK
Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
